We report a case of a female patient in her 40s who presented with right upper quadrant pain and abdominal discomfort. Surgical removal was not possible due to the location of the lesion. Between 2021 and 2022, the patient had four additional sessions of conventional transarterial embolization (TAE) with Lipiodol, but none succeeded in sufficiently reducing the hemangioma?s size or permanently improving the symptoms. In November 2022, we used transarterial chemoembolization (TACE) with a Bleomycin-Lipiodol emulsion. Follow-up MRI scans showed a gradual reduction in the hemangioma volume, but the symptoms only improved partially. Hence, the patient underwent a second bleomycin TACE embolization in November 2023. By August 2024, control showed a total volume reduction of 409 cmł (56%) and significant symptom improvement. This case demonstrates that Bleomycin-Lipiodol TACE can effectively reduce the size of giant liver hemangiomas, even after the failure of other interventional therapies.  Kulcsszavak: giant liver hemangioma, TACE, bleomycin